GAMMA Investing LLC Boosts Stock Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

GAMMA Investing LLC boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 10,665.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,921 shares of the company’s stock after acquiring an additional 5,866 shares during the quarter. GAMMA Investing LLC’s holdings in Monte Rosa Therapeutics were worth $41,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Monte Rosa Therapeutics by 23.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company’s stock valued at $5,538,000 after acquiring an additional 197,247 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Monte Rosa Therapeutics by 54.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 24,100 shares of the company’s stock valued at $128,000 after acquiring an additional 8,500 shares during the period. Renaissance Technologies LLC boosted its holdings in Monte Rosa Therapeutics by 108.6% during the 2nd quarter. Renaissance Technologies LLC now owns 254,714 shares of the company’s stock valued at $953,000 after acquiring an additional 132,614 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Monte Rosa Therapeutics by 14.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,877 shares of the company’s stock valued at $625,000 after acquiring an additional 15,168 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Monte Rosa Therapeutics during the 3rd quarter valued at $77,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Insider Transactions at Monte Rosa Therapeutics

In other news, major shareholder Versant Venture Capital Vi, L. sold 89,990 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $9.66, for a total value of $869,303.40. Following the completion of the transaction, the insider now directly owns 2,007,948 shares of the company’s stock, valued at approximately $19,396,777.68. The trade was a 4.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GLUE shares. Wells Fargo & Company cut Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $14.00 to $11.00 in a report on Thursday, December 19th. Wedbush reiterated an “outperform” rating and issued a $15.00 target price on shares of Monte Rosa Therapeutics in a report on Thursday, November 7th.

Monte Rosa Therapeutics Trading Down 0.7 %

Shares of GLUE stock opened at $5.66 on Tuesday. The stock has a market capitalization of $347.73 million, a price-to-earnings ratio of -3.09 and a beta of 1.47. Monte Rosa Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $12.40. The stock has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $6.28.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.16. The company had revenue of $9.22 million during the quarter, compared to the consensus estimate of $4.54 million. Research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current fiscal year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.